@article{b43525df3da2437b9f0c852f523a70b2,
title = "Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial",
abstract = "This study aimed to evaluate prognostic risk factors for cardiovascular events during treatment of metastatic prostate cancer patients with high-dose parenteral polyoestradiol phosphate (PEP, Estradurin{\textregistered}) or combined androgen deprivation (CAD) with special emphasis on pretreatment cardiovascular disease.",
keywords = "Aged, Antineoplastic Agents, Hormonal, Cardiovascular Diseases, Combined Modality Therapy, Estradiol, Estrogens, Flutamide, Humans, Infusions, Parenteral, Male, Neoplasm Metastasis, Orchiectomy, Prognosis, Prostatic Neoplasms, Risk Factors, Triptorelin Pamoate",
author = "Hedlund, {Per Olov} and Robert Johansson and Damber, {Jan Erik} and Inger Hagerman and Peter Henriksson and Peter Iversen and Klarskov, {Ole Peter} and Peter Mogensen and Finn Rasmussen and Eberhard Varenhorst and {SPCG-5 STUDY GROUP}",
year = "2011",
doi = "10.3109/00365599.2011.585820",
language = "English",
volume = "45",
pages = "346--53",
journal = "Scandinavian Journal of Urology and Nephrology",
issn = "0036-5599",
publisher = "Taylor & Francis",
number = "5",
}